(Q42431264)

31 October 2017

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing (English)

1 reference

31 October 2017

1 reference

2

Manfred Dietel

1 reference

31 October 2017

Josef Rüschoff

1

1 reference

31 October 2017

Gustavo Baretton

3

1 reference

31 October 2017

Susanne Arbogast

4

1 reference

31 October 2017

Axel Walch

5

1 reference

31 October 2017

Geneviéve Monges

6

1 reference

31 October 2017

Marie-Pierre Chenard

7

1 reference

31 October 2017

Frédérique Penault-Llorca

8

1 reference

31 October 2017

Iris Nagelmeier

9

1 reference

31 October 2017

Werner Schlake

10

1 reference

31 October 2017

H Höfler

11

1 reference

31 October 2017

H H Kreipe

12

1 reference

31 October 2017

28 July 2010

1 reference

31 October 2017

1 reference

31 October 2017

457

1 reference

31 October 2017

299-307

1 reference

31 October 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s00428-010-0952-2

31 October 2017

0 references

cites work

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

HER-2 amplification is highly homogenous in gastric cancer.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2933810

Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients

16 August 2018

1 reference

12 December 2020

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

1 reference

12 December 2020

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

12 December 2020

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

1 reference

12 December 2020

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification

1 reference

12 December 2020

Comparative study on overexpression of HER2/neu and HER3 in gastric cancer

1 reference

12 December 2020

Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer

1 reference

12 December 2020

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin

1 reference

12 December 2020

Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models

1 reference

12 December 2020

10.1007/S00428-010-0952-2

Identifiers

DOI

1 reference

Dimensions Publication ID

31 October 2017

0 references

1 reference

31 October 2017

1 reference